Risks of chemical substances to human health and the environment RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.
Use of other needles in Dutch Immunisation Programme as a precaution As a result of the EenVandaag broadcast regarding the safety of injection needles, and after consultation with the Dutch Inspection for Health Care (IGZ), RIVM advises against the use of needles so
New insights on ammonia emissions Calculated ammonia emissions in the Netherlands are still declining. However, emissions overall are greater than previously assumed.
Harmful substances in e-cigarettes assessed While e-cigarettes are less harmful to health than tobacco cigarettes, the vapour from an e-cigarette contains substances and chemical impurities in concentrations that could be detrimental to heal
Reduced-sodium lunches result in decreased daily dietary sodium intakes Consumption of reduced-sodium foods over a 3-week period was well accepted by uninformed participants in an experimental real-life canteen setting.
Utrecht Side Event International One Health Congress Scientists and policy makers from around the world will visit research institutes and companies in the field of Life Sciences in the Utrecht region on March 18th.
Big Data gives more insight into the health impacts of air pollution Long-term exposure to particulate air pollution and nitrogen dioxide has been found to be associated with total mortality and mortality from respiratory diseases and lung cancer in the Netherlands.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.